Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerable dose of the
combination of sunitinib and temsirolimus that can be given to patients with metastatic
kidney cancer.